-
MK-1775: Practical Wee1 Kinase Inhibitor Workflows
2026-08-16
Learn how to use MK-1775 to interrogate Wee1-dependent checkpoint control, distinguish growth arrest from cell death, and test chemotherapy sensitization in p53-deficient models. This workflow emphasizes mechanism-aligned controls, time-resolved readouts, and troubleshooting for interpretable combination data.
-
Carbapenemase Dissemination in CREC: Guangdong Study
2026-08-15
A 2025 BMC Microbiology study characterized carbapenemase-encoding genes in carbapenem-resistant Enterobacter cloacae collected from eight teaching hospitals in Guangdong, China, combining gene localization, antimicrobial susceptibility, conjugation, mobile-element analysis, and strain typing. Its findings show that blaNDM-1 was frequently plasmid-associated and readily transferable, providing a practical framework for interpreting multidrug resistance and transmission risk in hospital CREC surveillance.
-
From Cancer Mechanism to Translational Screening
2026-08-14
Mechanism-led screening can convert complex cancer biology into actionable translational hypotheses. This perspective connects the DHHC9–STRN4–YAP metastasis axis with pathway-focused use of the L1023 Anti-Cancer Compound Library, outlining how researchers can move from broad chemical discovery to biomarker-aware validation.
-
Ertapenem: From MIC to Gene Mobility
2026-08-14
Ertapenem sodium salt can do more than support susceptibility testing. This article presents a layered research framework that connects phenotype, carbapenemase gene location, plasmid transfer, and strain relatedness without confusing an MIC result with a complete resistance mechanism.
-
Tigecycline Workflows for MDR Bacteria Research
2026-08-13
Build reproducible Tigecycline workflows that connect antimicrobial susceptibility testing with plasmid biology and infection-model readouts. The approach is especially useful for MRSA, resistant Enterococcus, and carbapenem-resistant Enterobacter cloacae research, while keeping genotype–phenotype conclusions appropriately bounded.
-
5-hme-dCTP: Designing Causal Epigenetic Assays
2026-08-13
5-hme-dCTP enables controlled studies of DNA hydroxymethylation beyond descriptive mapping. Learn how this modified nucleotide supports polymerase validation, assay controls, and more rigorous interpretation of plant drought-response epigenetics.
-
(+)-JQ1 in AR-Heterogeneous Prostate Cancer
2026-08-12
Explore how the BET bromodomain inhibitor (+)-JQ1 can be used as an orthogonal probe in AR-heterogeneous prostate cancer models. This article connects chromatin biology, apoptosis assay design, and treatment-response stratification while distinguishing established evidence from testable hypotheses.
-
Drug Repurposing for CRISPR DNA Repair Control
2026-08-12
This reference study presents a large-scale pharmacological screen in human induced pluripotent stem cells to identify clinically used drugs that redirect CRISPR-induced double-strand break repair toward NHEJ, MMEJ, or HDR. Its findings connect repair-pathway control with genome editing precision and synthetic lethality, while highlighting ESR2 and AOX1 as mechanistic regulators that warrant further validation.
-
Lysosomal β-Galactosidase Staining Kit Guide
2026-08-11
Learn how the Lysosomal β-Galactosidase Staining Kit can function as a rigorous senescence-associated control in cancer research. This guide connects lysosomal enzyme detection with the SLC25A1–H3K27ac–senescence pathway while emphasizing assay interpretation, controls, and workflow quality.
-
Measuring Drug Response Beyond Viability Assays
2026-08-11
Hannah Schwartz’s dissertation shows why relative viability and fractional viability should not be treated as interchangeable readouts of anticancer activity. Its central contribution is a response framework that separates proliferative arrest from cell death and accounts for their different proportions and temporal dynamics, improving the interpretation of in vitro drug studies.
-
Arachidonic Acid Supplementation and Humoral Immunity
2026-08-10
A recent reference study identifies dietary arachidonic acid (ARA) as a potential nutritional adjuvant that accelerates rabies vaccine-induced neutralizing antibody responses in mice and human volunteers. Its central mechanistic contribution is linking lymph-node ARA metabolism to prostaglandin I2, cAMP-PKA signaling, CD86 expression, and activation-induced cytidine deaminase in B cells.
-
CNQX for AMPA/Kainate Signaling Studies
2026-08-09
CNQX is a practical way to separate AMPA/kainate-driven excitation from NMDA receptor activity in neuronal and neurocardiovascular assays. This guide translates its receptor pharmacology into controlled workflows, reference-study interpretation, and troubleshooting strategies for synaptic and excitotoxicity research.
-
Psoralen-Induced Cholestasis via ERK1/2
2026-08-08
The reference study shows that psoralen and isopsoralen, estrogen-like constituents of Psoraleae Fructus, induce cholestatic liver injury in zebrafish larvae through estrogen-associated signaling and ERK1/2 activation. Its integrated use of estrogenic biomarkers, bile-flow phenotyping, transporter-gene analysis, and pharmacological rescue identifies ERK1/2 as a mechanistic and experimentally testable target in phytoestrogen-associated cholestasis.
-
IGFRIL–PTBP1 Control of IGFBP3 in HCC
2026-08-07
The 2025 Advanced Science study identifies IGFRIL as a long non-coding RNA that activates IGF1R signaling in hepatocellular carcinoma by recruiting PTBP1 and destabilizing IGFBP3 mRNA. Its combination of transcriptome-wide discovery, mechanistic RNA analysis, and patient-derived xenograft testing links a non-coding regulator to a therapeutically actionable IGF1R–AKT–mTOR pathway.
-
Malate ((S)-2-hydroxysuccinic acid) in TCA Cycle Immune Rese
2026-08-07
Malate ((S)-2-hydroxysuccinic acid) empowers precise mapping of metabolic and immunological axes in cancer research, leveraging its role as a tricarboxylic acid cycle intermediate. APExBIO’s malate stands out for reproducibility and application flexibility, guiding advanced studies of mitochondrial signaling and immune modulation.